. 2019 Apr 26;14(4):e0215762. doi: 10.1371/journal.pone.0215762

Table 2. LOOCV serum mass profiling test metrics.

Group 1 vs. Group 2	Mean (SD) Group 1	Mean (SD) Group 2	TP	TN	FP	FN	P-Value, Cohen’s d	Random Grouping: P-Value	Figure #: panel
TBI (most affected), N = 21 vs. Controls, N = 20	58.16% (4.24%)	39.87% (3.80%)	21/21 (100%)	20/20 (100%)	0/20 (0%)	0/21 (0%)	1.3 x 10−¹⁷, 4.54	0.42	3: A & B
Training Set A: TBI (most affected), N = 16 vs. Controls, N = 15	58.50% (5.33%)	39.87% (4.07%)	16/16 (100%)	15/15 (100%)	0/15 (0%)	0/16 (0%)	1.4 x 10−¹³, 3.92	0.42	4: A & B
Blinded Set A: TBI (most affected), N = 16 vs. Controls, N = 15	51.90% (2.00%)	44.56% (3.28%)	5/5 (100%)	4/5 (80%)	1/5 (20%)	0/5 (0%)	2.1 x 10−³, 2.70	na	4: C
Training Set B: TBI (most affected), N = 15 vs. TBI, N = 12	60.80% (6.49%)	26.28% (5.18%)	15/15 (100%)	12/12 (100%)	0/12 (0%)	0/15 (0%)	1.50 x 10−¹⁴, 5.87	0.07	4: D
Blinded Samples B: (most affected), N = 6	46.71% (4.06%)	na	5/6 (83%)	na	na	1/6 (17%)	na	na	4: D
TBI; N = 12 vs. Controls, N = 20	73.13% (4.38%)	44.77% (4.31%)	12/12 (100%)	20/20 (100%)	0/20 (0%)	0/12 (0%)	2.81 x 10−¹⁵, 6.52	0.49	5: A
TBI +CM; N = 11 vs. Controls, N = 20	75.81% (5.28%)	40.91% (6.09%)	11/11 (100%)	20/20 (100%)	0/20 (0%)	0/11 (0%)	8.84 x 10−¹⁵, 6.12	0.04	5: B
TBI +CM; N = 11 vs. TBI; N = 12	67.41% (4.49%)	35.99% (7.62%)	11/11 (100%)	12/12 (100%)	0/12 (0%)	0/11 (0%)	1.98 x 10−¹⁰, 5.02	0.39	5: C

Mean of the % Total LOOCV Sera Mass Peaks (Standard Deviation [SD]); True Positives (TP); True Negatives (TN); False Positives (FP); False Negatives (FN); Traumatic Brain Injury (TBI); Chronic Migraine (CM); Post Traumatic Stress Disorder (PTSD); not applicable (na); TBI Most Affected (TBI, plus CM, plus PTSD, plus severe depression); Controls (minus TBI, no CM, minus PTSD, minus Depression); TBI +CM (TBI, plus CM, minimal/no PTSD, minimal/no Depression); TBI (TBI, minimal/no PTSD, no CM, plus minimal/no depression)